This study demonstrated that tumor cells were resistant to the reduction in blood flow through the increased OEF and it will be an effective treatment strategy to modulate the blood flow, such as therapy using bevacizumab with a monoclonal antibody targeting vascular endothelial growth factor which normalizes vascular architecture, to deliver anti-tumor drugs more effectively and enhance the radiosensitizing effect through oxygenation. This evidence concerns the gene VEGFA and neoplasm.